A theme concerning the arbitration with Novartis over the license agreement for Gilenya (FTY720), under which part of the royalties could not be temporarily recognized as revenue, and the unrecognized amount was recorded after the arbitral award. It addresses a legal dispute over royalty income from a specific drug and its impact on revenue recognition.